Mannatech settles class action
This article was originally published in The Tan Sheet
Executive Summary
Dietary supplement marketer Mannatech will pay $11.25 million to settle class action allegations that it caused its stock to trade at inflated levels between Aug. 10, 2004 and July 30, 2007 by failing to adequately monitor how its associates advertised its products. Approval by the U.S. District Court for the Northern District of Texas is required for the settlement to be finalized, but the Coppell, Texas-based firm says March 21 it expects approval without material changes within four to six months...
You may also be interested in...
Mannatech cuts costs with layoffs
The Coppell, Texas-based multi-level marketer will immediately eliminate roughly 15 percent of its U.S. workforce, or approximately 60 positions, as part of an effort to reduce expenses and "reposition the company for improved profitability," the supplement and skin care firm says July 10. The firm's cost-cutting measures also follow recent legal troubles. Mannatech agreed to pay $11.25 million in March to settle class action allegations that it caused its stock to trade at inflated levels between Aug. 10, 2004 and July 30, 2007 by failing to adequately monitor how its associates advertised its products (1"The Tan Sheet" March 24, 2008, In Brief)...
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip